Cargando…
Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil
A rapid and accurate diagnosis is a crucial strategy for containing the coronavirus disease (COVID-19) pandemic. Considering the obstacles to upscaling the use of RT–qPCR, rapid tests based on antigen detection (Ag-RDT) have become an alternative to enhance mass testing, reducing the time for a prom...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202877/ https://www.ncbi.nlm.nih.gov/pubmed/35709075 http://dx.doi.org/10.1371/journal.pone.0269997 |
_version_ | 1784728605968826368 |
---|---|
author | Freire, Mariana Lourenço Alves, Lindicy Leidicy de Souza, Carolina Senra Saliba, Juliana Wilke Faria, Verônica Pedras, Mariana Junqueira Carvalho, Nara de Oliveira Andrade, Gláucia Queiroz Rabello, Ana Avelar, Daniel Moreira Cota, Gláucia |
author_facet | Freire, Mariana Lourenço Alves, Lindicy Leidicy de Souza, Carolina Senra Saliba, Juliana Wilke Faria, Verônica Pedras, Mariana Junqueira Carvalho, Nara de Oliveira Andrade, Gláucia Queiroz Rabello, Ana Avelar, Daniel Moreira Cota, Gláucia |
author_sort | Freire, Mariana Lourenço |
collection | PubMed |
description | A rapid and accurate diagnosis is a crucial strategy for containing the coronavirus disease (COVID-19) pandemic. Considering the obstacles to upscaling the use of RT–qPCR, rapid tests based on antigen detection (Ag-RDT) have become an alternative to enhance mass testing, reducing the time for a prompt diagnosis and virus spreading. However, the performances of several commercially available Ag-RDTs have not yet been evaluated in several countries. Here, we evaluate the performance of eight Ag-RDTs available in Brazil to diagnose COVID-19. Patients admitted to tertiary hospitals with moderate or mild COVID-19 symptoms and presenting risk factors for severe disease were included. The tests were performed using a masked protocol, strictly following the manufacturer’s recommendations and were compared with RT–qPCR. The overall sensitivity of the tests ranged from 9.8 to 81.1%, and specificity greater than 83% was observed for all the evaluated tests. Overall, slight or fair agreement was observed between Ag-RDTs and RT–PCR, except for the Ag-RDT COVID-19 (Acro Biotech), in which moderate agreement was observed. Lower sensitivity of Ag-RDTs was observed for patients with cycle threshold > 25, indicating that the sensitivity was directly affected by viral load, whereas the effect of the disease duration was unclear. Despite the lower sensitivity of Ag-RDTs compared with RT–qPCR, its easy fulfillment and promptness still justify its use, even at hospital admission. However, the main advantage of Ag-RDTs seems to be the possibility of increasing access to the diagnosis of COVID-19 in patients with a high viral load, allowing immediate clinical management and reduction of infectivity and community transmission. |
format | Online Article Text |
id | pubmed-9202877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-92028772022-06-17 Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil Freire, Mariana Lourenço Alves, Lindicy Leidicy de Souza, Carolina Senra Saliba, Juliana Wilke Faria, Verônica Pedras, Mariana Junqueira Carvalho, Nara de Oliveira Andrade, Gláucia Queiroz Rabello, Ana Avelar, Daniel Moreira Cota, Gláucia PLoS One Research Article A rapid and accurate diagnosis is a crucial strategy for containing the coronavirus disease (COVID-19) pandemic. Considering the obstacles to upscaling the use of RT–qPCR, rapid tests based on antigen detection (Ag-RDT) have become an alternative to enhance mass testing, reducing the time for a prompt diagnosis and virus spreading. However, the performances of several commercially available Ag-RDTs have not yet been evaluated in several countries. Here, we evaluate the performance of eight Ag-RDTs available in Brazil to diagnose COVID-19. Patients admitted to tertiary hospitals with moderate or mild COVID-19 symptoms and presenting risk factors for severe disease were included. The tests were performed using a masked protocol, strictly following the manufacturer’s recommendations and were compared with RT–qPCR. The overall sensitivity of the tests ranged from 9.8 to 81.1%, and specificity greater than 83% was observed for all the evaluated tests. Overall, slight or fair agreement was observed between Ag-RDTs and RT–PCR, except for the Ag-RDT COVID-19 (Acro Biotech), in which moderate agreement was observed. Lower sensitivity of Ag-RDTs was observed for patients with cycle threshold > 25, indicating that the sensitivity was directly affected by viral load, whereas the effect of the disease duration was unclear. Despite the lower sensitivity of Ag-RDTs compared with RT–qPCR, its easy fulfillment and promptness still justify its use, even at hospital admission. However, the main advantage of Ag-RDTs seems to be the possibility of increasing access to the diagnosis of COVID-19 in patients with a high viral load, allowing immediate clinical management and reduction of infectivity and community transmission. Public Library of Science 2022-06-16 /pmc/articles/PMC9202877/ /pubmed/35709075 http://dx.doi.org/10.1371/journal.pone.0269997 Text en © 2022 Freire et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Freire, Mariana Lourenço Alves, Lindicy Leidicy de Souza, Carolina Senra Saliba, Juliana Wilke Faria, Verônica Pedras, Mariana Junqueira Carvalho, Nara de Oliveira Andrade, Gláucia Queiroz Rabello, Ana Avelar, Daniel Moreira Cota, Gláucia Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil |
title | Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil |
title_full | Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil |
title_fullStr | Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil |
title_full_unstemmed | Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil |
title_short | Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil |
title_sort | performance differences among commercially available antigen rapid tests for covid-19 in brazil |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202877/ https://www.ncbi.nlm.nih.gov/pubmed/35709075 http://dx.doi.org/10.1371/journal.pone.0269997 |
work_keys_str_mv | AT freiremarianalourenco performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil AT alveslindicyleidicy performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil AT desouzacarolinasenra performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil AT salibajulianawilke performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil AT fariaveronica performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil AT pedrasmarianajunqueira performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil AT carvalhonaradeoliveira performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil AT andradeglauciaqueiroz performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil AT rabelloana performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil AT avelardanielmoreira performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil AT cotaglaucia performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil |